Critical Survey: Amarillo Biosciences (OTCMKTS:AMAR) vs. Cyclacel Pharmaceuticals (NASDAQ:BGMS)

Cyclacel Pharmaceuticals (NASDAQ:BGMS) and Amarillo Biosciences (OTCMKTS:AMAR) are both small-cap manufacturing companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends and valuation.

Valuation & Earnings

This table compares Cyclacel Pharmaceuticals and Amarillo Biosciences”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclacel Pharmaceuticals	$750,000.00	6.70	-$3.00 million	($4.54)	-0.20
Amarillo Biosciences	$20,000.00	0.00	-$1.45 million	N/A	N/A

Amarillo Biosciences has lower revenue, but higher earnings than Cyclacel Pharmaceuticals.

Insider & Institutional Ownership

23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. 23.8% of Cyclacel Pharmaceuticals shares are owned by company insiders. Comparatively, 34.4% of Amarillo Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Cyclacel Pharmaceuticals has a beta of -0.4, meaning that its share price is 140% less volatile than the S&P 500. Comparatively, Amarillo Biosciences has a beta of -0.06, meaning that its share price is 106% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Cyclacel Pharmaceuticals and Amarillo Biosciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclacel Pharmaceuticals	1	0	0	0	1.00
Amarillo Biosciences	0	0	0	0	0.00

Given Amarillo Biosciences’ higher possible upside, analysts clearly believe Amarillo Biosciences is more favorable than Cyclacel Pharmaceuticals.

Profitability

This table compares Cyclacel Pharmaceuticals and Amarillo Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cyclacel Pharmaceuticals	N/A	-51.21%	-44.00%
Amarillo Biosciences	-41,453.98%	N/A	-574.29%

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing’s disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.

About Amarillo Biosciences

Amarillo Biosciences, Inc., a healthcare company, engages in the discovery and development of pharmaceutical and biotech products in the United States and Asia. The company operates in three divisions: Pharmaceutical, Medical, and Consumer. The Pharmaceutical division offers low-dose non-injectable interferon (IFN) for the treatment of neoplastic, viral, and fibrotic diseases. The Medical division focuses on medical devices and developing technology to treat metabolism related diseases, such as Type 1 and Type 2 diabetes. The Consumer division provides a range of nutraceutical and food supplement products that utilize a liposomal delivery system. It owns four issued patents related to the low-dose oral delivery of interferon; one patent is for a product promoting oral health; and three patents are associated with treatment of metabolic disorders. The company was incorporated in 1984 and is based in Amarillo, Texas.